Trump’s tariff impact likely ‘minimal’ for brand-name drugmakers news2025-02-10T18:22:08+00:00February 10th, 2025|Endpoints News|
Hims’ Super Bowl ad has drawn criticism from lawmakers — and now Novo Nordisknews2025-02-10T17:43:24+00:00February 10th, 2025|Endpoints News|
Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharmanews2025-02-10T14:53:43+00:00February 10th, 2025|Endpoints News|
AbbVie wins FDA approval for new antibioticnews2025-02-08T19:36:25+00:00February 8th, 2025|Endpoints News|
Sanofi, AstraZeneca back Teva’s call to rehear case on patent listingsnews2025-02-07T20:01:56+00:00February 7th, 2025|Endpoints News|
Belgian regulator recommends blocking Indian drugmaker’s API productionnews2025-02-07T18:17:14+00:00February 7th, 2025|Endpoints News|
Bristol Myers prunes pipeline amid new round of cost cutsnews2025-02-06T19:51:39+00:00February 6th, 2025|Endpoints News|
Updated: Hospital group blasts proposed 340B rebate models, requests to join lawsuits with HHSnews2025-02-06T19:02:11+00:00February 6th, 2025|Endpoints News|
AstraZeneca takes $753M charge on abandoned complement drug from Alexion dealnews2025-02-06T16:25:39+00:00February 6th, 2025|Endpoints News|
J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmakernews2025-02-06T16:17:39+00:00February 6th, 2025|Endpoints News|
